ArtNr |
HY-12594-50mg |
Hersteller |
MedChem Express
|
CAS-Nr. |
1216941-48-8 |
Menge |
50 mg |
Quantity options |
100 mg
10mM/1mL
10 mg
50 mg
5 mg
|
Kategorie |
|
Typ |
Inhibitors |
Specific against |
other |
Purity |
99.89 |
Formula |
C40H43N7O7S |
Citations |
[1]Smith MA,et al. Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection. Drug Des Devel Ther. 2015 Nov 13;9:6083-94.<br/>[2]Schnell G, et al. Hepatitis C Virus Genotype 4 Resistance and Subtype Demographic Characterization of Patients Treated with Ombitasvir plus Paritaprevir/ritonavir. Antimicrob Agents Chemother. 2015 Aug 17. pii: AAC.01229-15.<br/>[3]Qi Sun, et al. Bardoxolone and bardoxolone methyl, two Nrf2 activators in clinical trials, inhibit SARS-CoV-2 replication and its 3C-like protease. Signal Transduct Target Ther. 2021 May 29;6(1):212.<br/>[4]Menon RM, et al. Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir. J Hepatol. 2015 Jul;63(1):20-9. |
Smiles |
O=C([C@]1(NC([C@@]2([H])N3C[C@H](OC4=C(C=CC=C5)C5=C6C(C=CC=C6)=N4)C2)=O)[C@H](/C=C\CCCCC[C@H](NC(C7=NC=C(C)N=C7)=O)C3=O)C1)NS(=O)(C8CC8)=O |
ECLASS 10.1 |
32160490 |
ECLASS 11.0 |
32160490 |
UNSPSC |
12000000 |
Alias |
ABT-450; Veruprevir |
Lieferbar |
|
Product Description |
Paritaprevir (ABT-450) is a potent, orally active and antiviral non-structural protein 3/4A (NS3/4A) protease inhibitor with EC50s of 1 and 0.21 nM against HCV 1a and 1b, respectively. Paritaprevir is also a SARS-CoV 3CLpro inhibitor with an IC50 of 1.31 μM. Paritaprevir is metabolized primarily by cytochrome P450 (CYP) 3A. The plasma concentration and half-life of Paritaprevir can be enhanced by Ritonavir (a CYP450 inhibitor)[1][2][3][4]. |
StorageTemperature |
4°C (Powder, sealed storage, away from moisture and light) |
Shipping |
Room Temperature |
Manufacturers Applications |
COVID-19-anti-virus |
MolecularWeight |
765.88 |
Clinical Information |
Launched |
Manufacturers Research Area |
Infection |
Solubility |
DMSO : ≥ 125 mg/mL|H2O : ≥ 0.1 mg/mL |
Target |
HCV; HCV Protease; SARS-CoV |
Manufacturers Target |
HCV; HCV Protease; SARS-CoV |
Manufacturers Pathway |
Anti-infection; Metabolic Enzyme/Protease |
Manufacturers Product type |
Reference compound |
Hinweis: Die dargestellten Informationen und Dokumente (Bedienungsanleitung, Produktdatenblatt, Sicherheitsdatenblatt und Analysezertifikat) entsprechen unserem letzten Update und sollten lediglich der Orientierung dienen. Wir übernehmen keine Garantie für die Aktualität. Für spezifische Anforderungen bitten wir Sie, uns eine Anfrage zu stellen.
Alle Produkte sind nur für Forschungszwecke bestimmt. Nicht für den menschlichen, tierärztlichen oder therapeutischen Gebrauch.